270 related articles for article (PubMed ID: 23209008)
1. Mechanisms of current therapies for diabetes mellitus type 2.
Thulé PM
Adv Physiol Educ; 2012 Dec; 36(4):275-83. PubMed ID: 23209008
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological management of type 2 diabetes mellitus: an update.
El-Kaissi S; Sherbeeni S
Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
Moore KB; Saudek CD
Am J Ther; 2008; 15(5):484-91. PubMed ID: 18806525
[TBL] [Abstract][Full Text] [Related]
4. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
6. Use of non-insulin therapies for type 1 diabetes.
Garg SK; Michels AW; Shah VN
Diabetes Technol Ther; 2013 Nov; 15(11):901-8. PubMed ID: 24131372
[No Abstract] [Full Text] [Related]
7. Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!
Riddle MC
Diabetes Care; 2017 Mar; 40(3):291-300. PubMed ID: 28223444
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin (Januvia) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
[No Abstract] [Full Text] [Related]
9. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Pratley RE
J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
[No Abstract] [Full Text] [Related]
12. Managing postprandial glucose levels in patients with diabetes.
Tenzer-Iglesias P; Brunton S
J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
[No Abstract] [Full Text] [Related]
13. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
Lo MC; Lansang MC
Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
15. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
16. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
18. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Effects of Incretin-Based Therapies.
White WB; Baker WL
Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
[TBL] [Abstract][Full Text] [Related]
20. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
